NACA family member 4, pseudogeneGenealiases: FKSG17 · NACAP1
Q-omics provides the consensus-scored NACA4P profile across patient tissues and cancer cell-line models. NACA4P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NACA4P is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, NACA4P RNA expression shows 11,185 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, COAD, and UVM as cancer lineages where NACA4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NACA4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NACA4P survival associations across molecular data types. NACA4P RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NACA4P RNA expression–survival associations across cancer types. High NACA4P expression shows unfavorable associations in LIHC, BRCA and LUAD, but favorable associations in THCA, UCEC and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NACA4P RNA expression.
This table summarizes NACA4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NACA4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NACA4P shows higher tumor expression in COAD, KIRC, LUSC, KIRP, LIHC and LUAD. The COAD box plot shows higher NACA4P RNA expression in tumor versus normal tissue (log2 FC = +0.905, t-test p < 0.001).
This table shows molecular features associated with NACA4P in patient tissues and cancer cell lines. In patient samples, NACA4P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NACA4P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LUNG_SCLC.
